FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly, to poly-signal activation of MST cells apoptosis, which is carried out by thallium salts targeted delivery using MS2 phage surface-modified virions, containing cyclic ligand iRGD having high affinity to integrins avb3 and avb5 and covalently bound with shell and core to genomic RNA with thallium salts.
EFFECT: invention provides integrated, effective prolonged cytotoxic effect on local and metastatic MST cells accumulation while minimizing undesirable side effects on body healthy cells.
1 cl, 6 ex, 11 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ONCOLYTIC TREATMENT METHOD FOR BREAST CANCER | 2018 |
|
RU2695136C1 |
| METHOD FOR PRODUCING BACTERIOPHAGE HPV AND METHOD FOR PRODUCING MODIFIED BACTERIOPHAGE HPV | 2022 |
|
RU2790451C1 |
| RECTAL SUPPOSITORIES BASED ON MODIFIED BACTERIOPHAGE MS2 FOR TARGETED THERAPY OF MALIGNANT SOLID TUMOURS | 2019 |
|
RU2735828C1 |
| METHOD OF OBTAINING PARTICLES OF BACTERIOPHAGES OF LEVIVIRUS FAMILY | 2020 |
|
RU2811106C2 |
| METHOD OF PRODUCING VIRUS-LIKE BACTERIOPHAGE PARTICLE | 2024 |
|
RU2821694C1 |
| THERAPEUTIC AGENT FOR TREATING VIRAL HEPATITIS C | 2014 |
|
RU2568872C1 |
| MULTIFUNCTIONAL HYBRID RECOMBINANT PROTEIN MEDICINAL PRODUCTS FOR THE TREATMENT OF TUMOR DISEASES | 2022 |
|
RU2801367C1 |
| ANTIGEN FOR RECOMBINANT VACCINE AGAINST RUBELLA VIRUS | 2019 |
|
RU2709328C1 |
| VIRIONS AND VIRUS-LIKE PARTICLES OF ALTERNANTHERA MOSAIC VIRUS AS AMPLIFIERS OF IMMUNE RESPONSE | 2015 |
|
RU2639491C2 |
| COMPOSITION AND METHOD OF TUMOUR CURING | 2007 |
|
RU2500815C2 |
